AEON Biopharma AEON

AEON Biopharma, Inc. is a biopharmaceutical company focused on developing a botulinum toxin product candidate as a biosimilar to AbbVie Inc.'s Botox for therapeutic indications. The product candidate is manufactured by Daewoong Pharmaceutical under current good manufacturing practices in a facility approved by the U. S. Food and Drug Administration Health Canada and the European Medicines Agency. AEON Biopharma, Inc. holds exclusive development and distribution rights for this candidate in the United States Canada the European Union the United Kingdom and other international territories. The company's goal is to secure regulatory approval through a Section 351(k) biologics license application using Botox as the reference product for all therapeutic indications except cosmetic uses. AEON Biopharma, Inc. seeks to address the global therapeutic botulinum toxin market which it estimates to be at least three point three billion dollars based on AbbVie's reported revenues. The company has previously evaluated the candidate in clinical programs including a Phase 2 study for cervical dystonia and Phase 2 studies for chronic and episodic migraine. Although the migraine studies did not meet their primary endpoints the cervical dystonia study achieved its primary and key secondary endpoints providing safety and efficacy data. AEON Biopharma, Inc. has built a management team with experience in biopharmaceutical development and commercialization of botulinum toxin products. The company operates in the biopharmaceutical industry with a specific focus on the therapeutic botulinum toxin market.

AEON Biopharma, Inc. currently does not generate any revenue from product sales. The company anticipates receiving revenue only after obtaining regulatory approval for its botulinum toxin candidate and successfully commercializing the product. Revenue would be derived from the sale of the approved therapy to healthcare providers for the treatment of approved medical indications. The company expects that a biosimilar approval limited to therapeutic uses would allow it to avoid the averaging of lower cosmetic prices in reimbursement calculations. By isolating therapeutic sales AEON Biopharma, Inc. believes it could achieve a more favorable net price for physicians after rebates and discounts compared with existing products. The firm projects that successful commercialization could generate product sales in line with the size of the therapeutic botulinum toxin market. Until approval is obtained the company relies on external financing to fund its research and development and general corporate activities. AEON Biopharma, Inc. has not yet entered into any partnership or licensing arrangement that would generate royalty or milestone income.

AEON Biopharma, Inc. positions itself as a developer of a biosimilar that could separate therapeutic sales from cosmetic sales potentially improving reimbursement rates for physicians. Its primary competitors include AbbVie’s Botox Evolus’ Jeuveau and other botulinum toxin products such as Dysport and Xeomin. The company believes that a biosimilar approval limited to therapeutic uses would allow it to avoid the averaging of lower cosmetic prices in reimbursement calculations a structural advantage not shared by existing products. AEON Biopharma, Inc. benefits from exclusive rights granted by Daewoong to develop and distribute the candidate for therapeutic indications in major markets. The firm also cites the established manufacturing relationship with Daewoong and the prior use of the same toxin in approved cosmetic products as supportive factors for its development program. The global therapeutic botulinum toxin market is estimated to be at least three point three billion dollars providing a sizable opportunity for a new entrant. AEON Biopharma, Inc. intends to follow the 351(k) biosimilar pathway which requires demonstrating high similarity to the reference product with no clinically meaningful differences in safety purity or potency. The company has already conducted analytical studies showing a one hundred percent amino acid sequence match between its candidate and Botox based on liquid chromatography mass spectrometry analysis of thousands of peptides. AEON Biopharma, Inc. plans to engage with the U. S. Food and Drug Administration to advance its program toward a biologics license application for therapeutic indications.

AEON Biopharma, Inc. intends to serve physicians hospitals clinics and other healthcare providers that administer botulinum toxin therapies for conditions such as cervical dystonia chronic migraine spasticity and other approved indications. Target customers include neurologists pain specialists physiatrists and urologists who treat the aforementioned therapeutic indications. The company also expects to serve specialty clinics focused on movement disorders and headache centers that inject botulinum toxin for therapeutic purposes. AEON Biopharma, Inc. has not yet disclosed specific customer names as it remains at a pre revenue stage. The firm's commercial strategy will involve building a sales and marketing team capable of engaging with prescribers and purchasing groups. Reimbursement dynamics and payer policies are important considerations for the target customer base. The company expects that physicians will evaluate the product based on its efficacy safety and potential cost advantages relative to existing botulinum toxin therapies. AEON Biopharma, Inc. will rely on its exclusive rights and manufacturing support to fulfill supply commitments to its future customer base.